Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Dermatologic 1

Conditions

Melanoma 74Neoplasm Metastasis 11Uveal Melanoma 7Skin Neoplasms 6Neoplasms 5Small Cell Lung Carcinoma 1Skin Diseases 1Sarcoma 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Parathyroid Neoplasms 1Oligodendroglioma 1Melanoma, Cutaneous Malignant 1Melanoma Neoplasms 1Lung Neoplasms 1Kidney Neoplasms 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Ependymoma 1Colonic Neoplasms 1Carcinoma 1Carcinoid Tumor 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1Advanced Melanoma 1

Interventions

Peripheral Blood Stem Cell Transplantation 23fludarabine phosphate 20Cyclophosphamide 18Mycophenolic Acid 16Whole-Body Irradiation 15Cyclosporine 15Busulfan 12Tacrolimus 11Methotrexate 10Antilymphocyte Serum 9Radiotherapy 8Melphalan 8Etoposide 8pembrolizumab 7Methylprednisolone 6Filgrastim 6Sirolimus 4Prednisone 4Nivolumab 4sargramostim 3Vincristine 3Transplantation 3Therapeutics 3Polymerase Chain Reaction 3Cord Blood Stem Cell Transplantation 3Amplified Fragment Length Polymorphism Analysis 3mogamulizumab 2merphos 2bempegaldesleukin 2Voriconazole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Dacarbazine × Dermatologic × Clear all
NCT02288897 2022-01-19

PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

Provectus Pharmaceuticals

Phase 3 Terminated
20 enrolled 13 charts
Dermatologic

Melanoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡